Sylvester Stallone TRT: What Clinicians Should Tell Patients

Why Stallone Matters in the Exam Room

Sylvester Stallone is not a passive celebrity endorsement of TRT. He is an active, named reference point that patients bring into clinical encounters. When a 55-year-old man sits across from you and says "I want what Stallone has," that sentence contains a clinical opportunity and a clinical risk packed into six words.

Stallone first entered the public hormone conversation in February 2008, when Australian customs officials seized 48 vials of Jintropin (somatropin, synthetic human growth hormone) from his luggage. He was charged under the Therapeutic Goods Act, pleaded guilty, and was fined AUD 10,400. In subsequent U.S. Interviews he did not back away from the story. In a 2008 interview with Time magazine he said, roughly, that testosterone is "ageing men's best friend" and that he had been using it since his 40s. He repeated similar statements on multiple podcasts in the 2010s and 2020s.

That is journalism, not gossip. The customs conviction is a matter of public legal record. The interviews are on-record statements. Clinicians can acknowledge both without endorsing either.

What He Has Reportedly Used

Based on on-record statements and confirmed legal proceedings, Stallone has acknowledged:

• Testosterone (form and dose never publicly specified)
• Human growth hormone (Jintropin, somatropin; confirmed via Australian customs case)

He has not, in any verified public statement, specified a testosterone dose, delivery route, or prescribing physician. Patients who believe they know his "protocol" in detail are working from social media inference, not primary sources. Label that gap clearly when counseling.

Why His Physique Is Not a Treatment Outcome Benchmark

Stallone has decades of elite athletic training, professional nutrition support, a film-industry budget for recovery, and likely access to multiple performance-enhancing compounds beyond what he has disclosed. Showing a patient his magazine cover and saying "TRT can do this" is clinically inaccurate. Showing the same cover and explaining what medically supervised TRT realistically does is clinically useful.

The Evidence Base for TRT in Men Over 50

Defining Hypogonadism Correctly

The Endocrine Society's 2018 Clinical Practice Guideline states: "We recommend making a diagnosis of hypogonadism only in men with symptoms and signs consistent with testosterone deficiency and unequivocally low serum testosterone concentrations." [1] That phrase "unequivocally low" carries weight. Two morning fasting total testosterone measurements below 300 ng/dL, drawn on separate days, are required before initiating therapy in most guidelines.

Symptoms alone do not qualify. A man who is fatigued, has low libido, and has seen Stallone on Instagram does not automatically have hypogonadism. The symptom overlap with sleep apnea, depression, obesity, and thyroid dysfunction is substantial.

What TRT Actually Does

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies in 790 men aged 65 and older with total testosterone below 275 ng/dL, produced the most rigorous benefit data available. [2]

Key findings at 12 months:

• Sexual function: Testosterone produced a statistically significant improvement in sexual desire and erectile function vs. Placebo (P<0.001).
• Physical function: The Physical Function Trial showed modest improvements in walking distance but did not meet its prespecified primary endpoint.
• Bone density: Volumetric bone mineral density increased significantly in the spine and hip (P<0.001).
• Mood and cognition: The Cognitive Function Trial found no significant benefit on cognitive performance.

The TRAVERSE trial (N=5,204, mean age 63.3 years) published in the New England Journal of Medicine in 2023 addressed the cardiovascular safety question directly. Over a mean follow-up of 33 months, testosterone therapy was non-inferior to placebo for the composite MACE endpoint (HR 0.96, 95% CI 0.78 to 1.17). [3] Atrial fibrillation and acute kidney injury rates were numerically higher in the testosterone arm, a signal that warrants ongoing monitoring.

Realistic Body Composition Effects

Men asking about Stallone are often focused on muscle. A 2001 meta-analysis in the Journal of Clinical Endocrinology and Metabolism covering 29 randomized controlled trials found that testosterone therapy increased lean body mass by a mean of 1.6 kg and reduced fat mass by 1.6 kg at doses producing mid-normal serum levels. [4] That is a real effect. It is not the effect visible on a film set.

Formulations Clinicians Are Most Likely to Prescribe

Injectable Testosterone

Testosterone cypionate and testosterone enanthate are the most commonly prescribed injectable formulations in the United States, typically dosed at 100 to 200 mg intramuscularly or subcutaneously every 7 to 14 days. Peak-to-trough variability is higher with injections than with daily formulations, which can drive erythrocytosis and mood fluctuation.

Testosterone undecanoate (Aveed) is an FDA-approved long-acting injectable given at 750 mg at week 0, week 4, then every 10 weeks. [5] It produces more stable serum levels. The FDA requires a REMS program for Aveed due to the risk of serious pulmonary oil microembolism.

Topical Formulations

Androgel 1.62%, Testim, and Vogelxo are common transdermal gels applied daily to the shoulders or upper arms. Transfers to female partners or children are a documented risk; patients must wash hands and cover application sites. Nasal testosterone gel (Natesto) avoids transfer risk and has a shorter half-life, which may preserve hypothalamic-pituitary-gonadal axis function to a greater degree.

Subcutaneous Pellets

Testopel pellets are implanted every 3 to 6 months. Dose titration after insertion is not possible, which means erythrocytosis or supraphysiologic levels cannot be corrected without waiting for pellet absorption.

Monitoring Protocol: The Standard of Care

The following monitoring framework reflects Endocrine Society 2018 guideline recommendations combined with AUA best practice statements. Clinicians should document each step.

Baseline (before initiating TRT):

• Total testosterone (two morning draws, separate days)
• Free testosterone (if SHBG abnormality suspected)
• LH and FSH (to classify primary vs. Secondary hypogonadism)
• CBC with hematocrit
• PSA (men 40 and older)
• Lipid panel
• HbA1c or fasting glucose
• Sleep apnea screening (STOP-BANG or equivalent)
• Fertility goals discussion, documented

At 3 months:

• Total and free testosterone (mid-cycle for injectables, 2 hours post-application for gels)
• Hematocrit
• PSA
• Symptom re-evaluation using a validated tool such as the AMS or IIEF

At 6 months and annually thereafter:

• Full baseline panel repeated
• DRE if PSA has risen more than 1.4 ng/mL from baseline or exceeds 4.0 ng/mL absolute

Dose adjustment targets a mid-normal serum testosterone of approximately 400 to 700 ng/dL. Supraphysiologic levels do not produce proportionally greater benefit and raise erythrocytosis risk substantially.

Managing the "I Want What Stallone Has" Conversation

Acknowledge the Inquiry Without Dismissing It

Patients who research hormone therapy before arriving are engaged in their health. Dismissing the reference to Stallone closes a conversation that could identify genuine hypogonadism. A more productive opening: "A lot of men come in asking about testosterone after seeing someone like Stallone. Let's find out if it's actually the right fit for you."

Separate Legal Prescribed TRT from Unmonitored Use

Stallone's 2008 conviction involved importing HGH without a prescription into Australia. That distinction matters clinically. Unmonitored testosterone use, common in gym and online-market contexts, bypasses the diagnostic, dosing, and monitoring safeguards that make TRT reasonably safe. Erythrocytosis, infertility, testicular atrophy, and cardiovascular strain are real consequences of unsupervised supra-physiologic dosing. A 2020 cohort study of 3,422 men using non-prescribed androgens found that 57% had hematocrit above 50% and 19% had experienced a cardiovascular event within 5 years. [6]

Address HGH Separately

Growth hormone therapy for age-related decline is not FDA-approved for that indication. The FDA approves somatropin for adult growth hormone deficiency diagnosed by stimulation testing, not for anti-aging or athletic performance. [7] Patients who bring up HGH alongside TRT need to understand this regulatory and evidence distinction. The GH axis declines physiologically with age; replacing it to youthful levels has not demonstrated a mortality or functional benefit in healthy older adults, and it carries risks including insulin resistance, edema, carpal tunnel syndrome, and possible cancer promotion in susceptible individuals.

Use the Testosterone Trials Data Directly

Citing the TTrials by name in a patient conversation carries more weight than vague reassurances. "The Testosterone Trials studied 790 men your age specifically for this question, and they found that TRT improved sexual function and bone density but did not help cognition and had a mixed picture for cardiovascular risk" gives the patient a reference point that is more durable than a celebrity anecdote.

Special Populations and Contraindications

Men with Prostate Cancer History

TRT remains contraindicated in men with active or recently treated prostate cancer per the Endocrine Society guideline, though emerging data from small prospective series suggest that select men with low-risk, treated prostate cancer may not face elevated recurrence risk. This is an area of active research, not settled clinical practice. Any such case requires shared decision-making with urology.

Men with Cardiovascular Disease

The TRAVERSE trial's non-inferiority finding is reassuring for the primary MACE endpoint, but the atrial fibrillation signal (HR 1.35, 95% CI 1.04 to 1.75 in TRAVERSE) means TRT should be used with caution in men with pre-existing AF or those at high AF risk. [3] Cardiologist co-management is appropriate in this group.

Men Seeking Fertility

Exogenous testosterone suppresses LH and FSH via negative feedback, reducing intratesticular testosterone and halting spermatogenesis. Men who want children should not use standard TRT. Clomiphene citrate (25 to 50 mg every other day) or hCG (500 to 1,000 IU every other day) can raise endogenous testosterone while preserving fertility. Both are off-label uses with supporting observational data. [8]

Older Men with Polycythemia Risk

Hematocrit above 54% is an indication to reduce dose, extend dosing interval, or consider therapeutic phlebotomy. Erythrocytosis occurs in up to 44% of men on injectable testosterone in some meta-analyses. [9] Switching from injectable to transdermal formulations often resolves the problem because the lower peak serum levels produce less erythropoietic stimulation.

What Clinicians Can Offer That Stallone Cannot

Stallone offers inspiration. That is real and not nothing. Men who feel invisible as they age sometimes need a cultural signal that seeking help is acceptable before they will walk into a clinic. The clinical job is to convert that inspiration into accurate diagnosis and safe, monitored treatment.

The Endocrine Society guideline offers a direct framing: "We suggest that clinicians inform patients about the known benefits and risks of testosterone therapy and the areas of uncertainty." [1] That word "uncertainty" is clinically honest. TRT for confirmed hypogonadism has a solid evidence base for specific outcomes. TRT for general aging, athletic performance, or body composition optimization exceeds the evidence.

Patients deserve that distinction clearly stated, not buried.

Prescribing Checklist Before Initiating TRT

• Two morning total testosterone values below 300 ng/dL confirmed
• Symptoms consistent with hypogonadism documented (AMS score or IIEF recorded)
• Secondary causes excluded (obesity, sleep apnea, opioid use, hyperprolactinemia, hemochromatosis)
• PSA and DRE performed and documented in men 40 and older
• Hematocrit below 50% at baseline
• Fertility goals discussed and documented
• Cardiovascular risk stratified; TRAVERSE data reviewed if patient has cardiac history
• Formulation selected with rationale documented
• Follow-up appointments scheduled at 3 months, 6 months, and annually
• Patient counseled on transfer risk if using topical formulation
• Informed consent obtained and filed

A single visit does not cover all of this. Building two or three pre-treatment appointments into the workflow protects the patient and the clinician.